IP Library Granted Patent US 7,767,453
Granted Patent B2
US 7,767,453 · App. 11/255,191 · Granted Aug 3, 2010

Cultured hematopoietic stem cells and method for expansion and analysis thereof

Assignee: Whitehead Institute for Biomedical Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,767,453
App. No.
11/255,191
Granted
Aug 3, 2010
Kind
B2
Abstract

Hematopoietic stem cells and methods for ex vivo expansion of hematopoietic stem cells are provided. The methods comprise culturing the cells in a media containing an effective amount insulin-like growth factor (IGF), fibroblast growth factor (FGF), thrombopoietin (TPO), and stem cell factor (SCF), under conditions sufficient for expansion of said cells. Methods for identifying expanded hematopoeitc stem cells and kits for ex vivo expansion of hematopoietic stem cells are also provided.

Claims (27)

1. A method for expanding hematopoietic stem cells ex vivo, comprising culturing a population of cells that includes hematopoietic stem cells in a medium comprising insulin-like growth factor-2 (IGF-2) and at least one factor selected from the group consisting of fibroblast growth factor (FGF), thrombopoietin (TPO), and stem cell factor (SCF), under conditions sufficient for expansion of the hematopoietic stem cells, thereby expanding hematopoietic stem cells ex vivo.

2. The method of claim 1 , wherein at least two factors from the group are present in the medium.

3. The method of claim 1 , wherein at least three factors from the group are present in the medium.

4. The method of claim 1 , wherein the FGF is FGF-1.

5. The method of claim 1 , wherein the medium comprises IGF-2, FGF-1, SCF, and TPO.

6. The method of claim 1 , wherein the IGF-2 is present at a concentration of about 20 ng/ml.

7. The method of claim 1 , wherein FGF is present at a concentration of about 10 ng/ml.

8. The method of claim 1 , wherein TPO is present at a concentration of about 20 ng/ml.

9. The method of claim 1 , wherein SCF is present at a concentration of about 10 ng/ml.

10. The method of claim 1 , wherein the cells are cultured for about two weeks.

11. The method of claim 1 , wherein said population of cells comprises total bone marrow.

12. The method of claim 1 , wherein said population of cells comprises a sub-population of total bone marrow cells.

13. The method of claim 1 , wherein the expanded hematopoietic stem cells are at least about 8-fold enriched for long term hematopoietic stem cells.

14. The method of claim 1 , wherein said culture medium comprises serum-free medium.

15. The method of claim 1 , further comprising the step of separating cells from the population of cells.

16. The method of claim 15 , wherein said separating is performed after culturing said population of cells.

17. The method of claim 15 , wherein the step of separating comprises selecting cells that express Kit.

18. The method of claim 17 , where the step of separating comprises selecting cells that express IGF-2 receptor.

19. The method of claim 15 , wherein the step of separating comprises selecting cells that express Kit and IGF-2 receptor.

20. The method of claim 15 , wherein the step of separating comprises selecting cells that do not express at least one negative cell surface marker.

21. The method of claim 20 , wherein the step of separating is performed after culturing said population of cells.

22. The method of claim 20 , wherein the step of separating comprises selecting cells that do not express Lin.

23. The method of claim 1 , further comprising the step of separating cells the population of cells by selecting cells that express at least one positive cell surface marker and that do not express at least one negative cell surface marker.

24. The method of claim 23 , wherein the step of separating is performed after culturing said population of cells.

25. The method of claim 23 , wherein the method comprises selecting cells that express Kit and that do not express Lin.

26. The method of claim 25 , wherein the method comprises selecting cells that express IGF-2 receptor.

27. The method of claim 23 , wherein the method comprises selecting cells that express IGF-2 receptor and that do not express Lin.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 31, 2014
From: WHITEHEAD INSTITUTE FOR BIOMEDICAL RES
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 033452/0981 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2006
From: ZHANG, CHENGCHENG; LODISH, HARVEY
To: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
Reel/Frame 017180/0615 →
Continuity (2)
Provisional Application 6062050900 · Oct 20, 2004
Related Publication 20060115898A1 · Jun 1, 2006